» Articles » PMID: 34638407

Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Oct 13
PMID 34638407
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The implications of intratumor heterogeneity on the four consensus molecular subtypes (CMS) of colorectal cancer (CRC) are not well known. Here, we use single-cell RNA sequencing (scRNASeq) to build an algorithm to assign CMS classification to individual cells, which we use to explore the distributions of CMSs in tumor and non-tumor cells. A dataset of colorectal tumors with bulk RNAseq ( = 3232) was used to identify CMS specific-marker gene sets. These gene sets were then applied to a discovery dataset of scRNASeq profiles ( = 10) to develop an algorithm for single-cell CMS (scCMS) assignment, which recapitulated the intrinsic biology of all four CMSs. The single-cell CMS assignment algorithm was used to explore the scRNASeq profiles of two prospective CRC tumors with mixed CMS via bulk sequencing. We find that every CRC tumor contains individual cells of each scCMS, as well as many individual cells that have enrichment for features of more than one scCMS (called mixed cells). scCMS4 and scCMS1 cells dominate stroma and immune cell clusters, respectively, but account for less than 3% epithelial cells. These data imply that CMS1 and CMS4 are driven by the transcriptomic contribution of immune and stromal cells, respectively, not tumor cells.

Citing Articles

Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.

Chowdhury S, Xiu J, Ribeiro J, Nicolaides T, Zhang J, Korn W Br J Cancer. 2024; 131(8):1328-1339.

PMID: 39227409 PMC: 11473766. DOI: 10.1038/s41416-024-02826-0.


Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer.

Langerud J, Eilertsen I, Moosavi S, Klokkerud S, Reims H, Backe I Nat Commun. 2024; 15(1):4342.

PMID: 38773143 PMC: 11109119. DOI: 10.1038/s41467-024-48706-2.


Single cell analyses of cancer cells identified two regulatorily and functionally distinct categories in differentially expressed genes among tumor subclones.

Cao W, Wang X, Luo K, Li Y, Sun J, Fu R Heliyon. 2024; 10(6):e28071.

PMID: 38524605 PMC: 10958426. DOI: 10.1016/j.heliyon.2024.e28071.


Gas-Phase Fractionation Data-Independent Acquisition Analysis of 3D Cocultured Spheroid Tumor Model Reveals Altered Translational Processes and Signaling Using Proteomics.

Shannon A, Boos C, Searle B, Hummon A J Proteome Res. 2024; 23(8):3188-3199.

PMID: 38412258 PMC: 11296903. DOI: 10.1021/acs.jproteome.3c00786.


Stromal Signals Dominate Gene Expression Signature Scores That Aim to Describe Cancer Cell-intrinsic Stemness or Mesenchymality Characteristics.

Kreis J, Aybey B, Geist F, Brors B, Staub E Cancer Res Commun. 2024; 4(2):516-529.

PMID: 38349551 PMC: 10885853. DOI: 10.1158/2767-9764.CRC-23-0383.


References
1.
Zhu X, Tian X, Ji L, Zhang X, Cao Y, Shen C . A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. NPJ Precis Oncol. 2021; 5(1):7. PMC: 7881244. DOI: 10.1038/s41698-021-00142-x. View

2.
Biller L, Schrag D . Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021; 325(7):669-685. DOI: 10.1001/jama.2021.0106. View

3.
Trinh A, Trumpi K, de Sousa E Melo F, Wang X, de Jong J, Fessler E . Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. Clin Cancer Res. 2016; 23(2):387-398. DOI: 10.1158/1078-0432.CCR-16-0680. View

4.
Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A . Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol. 2019; 30(4):520-527. PMC: 6503627. DOI: 10.1093/annonc/mdz052. View

5.
Matsuyama T, Kandimalla R, Ishikawa T, Takahashi N, Yamada Y, Yasuno M . A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. Int J Cancer. 2020; 147(11):3250-3261. PMC: 9192151. DOI: 10.1002/ijc.33129. View